References
Bhat SR, Goodwin TL, Burwinkle TM et al (2005) Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol 23:5493–5500
Bull KS, Spoudeas HA, Yadegarfar G et al (2007) Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors—On behalf of the CCLG (formerly UKCCSG). J Clin Oncol 25:4239–4245
Ellison DW, Dalton J, Kocak M et al (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381–396
Ellison DW, Kocak M, Dalton J et al (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400–1407
Kennedy C, Bull K, Chevignard M et al (2014) Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. Int J Radiat Oncol Biol Phys 88:292–300
Konczak J, Schoch B, Dimitrova A et al (2005) Functional recovery of children and adolescents after cerebellar tumour resection. Brain 128:1428–1441
Palmer SL, Armstrong C, Onar-Thomas A et al (2013) Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol 31:3494–3500
Schwalbe EC, Williamson D, Lindsey JC et al (2013) DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125:359–371
Taylor MD, Northcott PA, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465–472
Taylor RE, Bailey CC, Robinson K et al (2003) Results of a randomized study of pre-radiation chemotherapy versus radiotherapy alone for non-metastatic medulloblastoma: the International Society of Paediatric Oncology United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21:1581–1591
Wefers AK, Warmuth-Metz M, Pöschl J et al (2014) Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathol 127:931–933
Acknowledgments
This work was conducted on behalf of the UK Children’s Cancer and Leukemia Group (CCLG), and was supported by Grants from The Brain Tumour Charity and Cancer Research UK. Medulloblastomas investigated in this study were provided as part of CCLG approved biological study BS-2007-04. This study was conducted with ethics committee approval from Newcastle/North Tyneside and Trent RECs (study reference numbers 07/Q0905/71; MREC/02/4/019). The task of identifying associations between biological subtype and quality of survival was made possible by funding from the European Union’s Seventh Framework Programme (FP7/2007-13) under the project ENCCA, grant agreement HEALTH-F2-2011-261474.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bull, K.S., Kennedy, C.R., Bailey, S. et al. Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors. Acta Neuropathol 128, 151–153 (2014). https://doi.org/10.1007/s00401-014-1300-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-014-1300-4